Published in Malar J on June 11, 2008
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Retracted A Study on Course of Infection and Haematological Changes in falciparum-Infected in Comparison with Artemisinin(s)-Treated Mice. Malar Res Treat (2013) 1.47
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One (2010) 1.42
Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One (2010) 1.27
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J (2009) 1.12
Safety profile of Coartem: the evidence base. Malar J (2009) 1.09
Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J (2008) 1.02
Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J (2013) 0.94
An economic evaluation of home management of malaria in Uganda: an interactive Markov model. PLoS One (2010) 0.93
Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed? Am J Trop Med Hyg (2014) 0.81
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS One (2017) 0.75
Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Malar J (2016) 0.75
Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J (2014) 0.75
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Malaria. Lancet (2005) 7.37
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 3.40
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg (2006) 2.79
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg (2004) 2.49
Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J (2006) 2.48
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J (2007) 2.26
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg (2006) 1.88
Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. Malar J (2006) 1.81
Amodiaquine for treating malaria. Cochrane Database Syst Rev (2003) 1.71
A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Trans R Soc Trop Med Hyg (2006) 1.62
A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am J Trop Med Hyg (2006) 1.45
Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med (1990) 1.36
An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg (2000) 1.35
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg (2005) 1.29
No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg (1999) 1.28
Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev (2005) 1.28
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24
The WHO 'Roll Back Malaria Project': planning for adverse event monitoring in Africa. Drug Saf (2005) 1.19
Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. Trop Med Int Health (2006) 0.96
Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg (2002) 0.96
Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. Am J Trop Med Hyg (2007) 0.85
How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf (1993) 0.82
Antimalarial drug combinations in vastly different settings. Lancet (2007) 0.80
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis (2010) 4.08
Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J (2007) 4.05
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis (2010) 2.90
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
Acceptability of routine HIV counselling and testing, and HIV seroprevalence in Ugandan hospitals. Bull World Health Organ (2008) 2.80
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J (2008) 2.78
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J (2006) 2.48
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? Lancet Infect Dis (2009) 2.46
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg (2006) 2.43
Improved malaria case management after integrated team-based training of health care workers in Uganda. Am J Trop Med Hyg (2008) 2.42
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42
Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc Natl Acad Sci U S A (2004) 2.33
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg (2007) 2.30
Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis (2008) 2.28
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
Plasmodium infection and its risk factors in eastern Uganda. Malar J (2010) 2.13
Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother (2007) 2.12
Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health (2015) 2.10
Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence. Malar J (2007) 2.08
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One (2009) 2.05
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05